| |
Τελευταία Νέα
-
Distribution agreement
On Tuesday 5 May 2009 Genekor and DiaGenic signed the distribution agreement which will make unique blood based gene expression tests for devastating diseases available for the Greek market.
DiaGenic, an innovative Norwegian life sciences company, produces blood based gene expression tests for early detection of Alzheimer's disease (ADtect®) and Breast Cancer (BCtect®).
ADtect® is the world's first blood based gene expression test in the early detection of Alzheimer's disease. The test detects unusual patterns of gene activity in a person's blood, which indicates the presence of Alzheimer's disease. ADtect® is a convenient add-on test to existing clinical examination to improve appropriate Alzheimer's disease detection.
Early detection will help identify the most appropriate health care service for the individual Alzheimer patient. The results of ADtect® will typically be available within 7 days from when the sample is taken.
BCtect® is a blood based test for early detection of breast cancer. The DiaGenic BCtect® detects unusual patterns of gene activity in a person's blood which indicates the presence of breast cancer. If the test is positive further investigation is required to establish the final diagnosis.
The test is as effective in detecting breast cancer in pre-menopausal women as in post-menopausal women. Many reports document that mammography is less effective in pre-menopausal women because breast tissue is denser.
BCtect® is therefore useful in pre-menopausal women and women with high breast density. Studies also show that BCtect® effectively detects lobular carcinomas, which often lack micro-calcifications and can be more difficult to detect by conventional mammography.
BCtect® could be used alongside mammography in women who have normal mammograms, but are particularly anxious about having breast cancer.
The results of BCtect® will typically be available within 7 days from sample is taken.
|
|
